Chapter 20: Issues in planning cervical cancer screening in the era of HPV vaccination.

[1]  J. Cuzick,et al.  Overview of the European and North American studies on HPV testing in primary cervical cancer screening , 2006, International journal of cancer.

[2]  S. Walter,et al.  Randomized controlled trial of human papillomavirus testing versus Pap cytology in the primary screening for cervical cancer precursors: Design, methods and preliminary accrual results of the Canadian cervical cancer screening trial (CCCaST) , 2006, International journal of cancer.

[3]  C. Wheeler,et al.  Sustained efficacy up to 4·5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial , 2006, The Lancet.

[4]  G. Zimet.  Understanding and overcoming barriers to human papillomavirus vaccine acceptance. , 2006, Current opinion in obstetrics & gynecology.

[5]  C. Wheeler,et al.  Efficacy of Human Papillomavirus-16 Vaccine to Prevent Cervical Intraepithelial Neoplasia: A Randomized Controlled Trial , 2006, Obstetrics and gynecology.

[6]  G. Zimet.  Improving adolescent health: focus on HPV vaccine acceptance. , 2005, The Journal of adolescent health : official publication of the Society for Adolescent Medicine.

[7]  G. Zimet,et al.  Attitudes about human papillomavirus vaccine among family physicians. , 2005, Journal of pediatric and adolescent gynecology.

[8]  C. Wheeler,et al.  Human papillomavirus type 16 infections and 2-year absolute risk of cervical precancer in women with equivocal or mild cytologic abnormalities. , 2005, Journal of the National Cancer Institute.

[9]  R. DeSalle,et al.  The carcinogenicity of human papillomavirus types reflects viral evolution. , 2005, Virology.

[10]  S. Franceschi,et al.  Human Papillomavirus Genotype Distribution in Low-Grade Cervical Lesions: Comparison by Geographic Region and with Cervical Cancer , 2005, Cancer Epidemiology Biomarkers & Prevention.

[11]  Cosette M Wheeler,et al.  Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. , 2005, The Lancet. Oncology.

[12]  C. Wheeler,et al.  Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: A randomized, controlled trial , 2005 .

[13]  Daron G Ferris,et al.  Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial , 2004, The Lancet.

[14]  Milton C Weinstein,et al.  Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. , 2004, Journal of the National Cancer Institute.

[15]  Vicki B Benard,et al.  Cervical Screening in the National Breast and Cervical Cancer Early Detection Program, 1995–2001 , 2004, Obstetrics and gynecology.

[16]  U Menon,et al.  Management of women who test positive for high-risk types of human papillomavirus: the HART study , 2003, The Lancet.

[17]  Shalini L Kulasingam,et al.  Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. , 2003, JAMA.

[18]  E. Franco.  Chapter 13: Primary screening of cervical cancer with human papillomavirus tests. , 2003, Journal of the National Cancer Institute. Monographs.

[19]  E. Franco,et al.  Human papillomavirus testing for primary screening of cervical cancer precursors. , 2000, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[20]  Evan R. Myers,et al.  Accuracy of the Papanicolaou Test in Screening for and Follow‐up of Cervical Cytologic Abnormalities: A Systematic Review , 2001 .